Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more
Hunan Jingfeng Pharmaceutical (000908) - Total Assets
Latest total assets as of September 2025: CN¥877.99 Million CNY
Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) holds total assets worth CN¥877.99 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hunan Jingfeng Pharmaceutical - Total Assets Trend (1995–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hunan Jingfeng Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Hunan Jingfeng Pharmaceutical's total assets of CN¥877.99 Million consist of 24.2% current assets and 75.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.1% |
| Accounts Receivable | CN¥81.96 Million | 8.7% |
| Inventory | CN¥44.18 Million | 4.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥163.82 Million | 17.4% |
| Goodwill | CN¥116.91K | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Jingfeng Pharmaceutical's current assets represent 24.2% of total assets in 2024, a decrease from 50.7% in 1995.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2024, down from 9.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 4.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 17.4% of total assets.
Hunan Jingfeng Pharmaceutical Competitors by Total Assets
Key competitors of Hunan Jingfeng Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Hunan Jingfeng Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hunan Jingfeng Pharmaceutical generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Hunan Jingfeng Pharmaceutical generates $ 16.20 in net profit.
Hunan Jingfeng Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | 0.20 | 0.55 |
| Quick Ratio | 0.32 | 0.14 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-480.78 Million | CN¥ -834.47 Million | CN¥ -836.79 Million |
Hunan Jingfeng Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hunan Jingfeng Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 157.09 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -11.4% |
| Total Assets | CN¥939.98 Million |
| Market Capitalization | $202.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Jingfeng Pharmaceutical's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hunan Jingfeng Pharmaceutical's assets decreased by 11.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hunan Jingfeng Pharmaceutical (1995–2024)
The table below shows the annual total assets of Hunan Jingfeng Pharmaceutical from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥939.98 Million | -11.35% |
| 2023-12-31 | CN¥1.06 Billion | -27.79% |
| 2022-12-31 | CN¥1.47 Billion | -18.07% |
| 2021-12-31 | CN¥1.79 Billion | -33.37% |
| 2020-12-31 | CN¥2.69 Billion | -38.16% |
| 2019-12-31 | CN¥4.35 Billion | -16.78% |
| 2018-12-31 | CN¥5.23 Billion | +7.36% |
| 2017-12-31 | CN¥4.87 Billion | -5.17% |
| 2016-12-31 | CN¥5.13 Billion | +49.13% |
| 2015-12-31 | CN¥3.44 Billion | +79.89% |
| 2014-12-31 | CN¥1.91 Billion | +468.26% |
| 2013-12-31 | CN¥336.78 Million | -9.01% |
| 2012-12-31 | CN¥370.13 Million | -12.18% |
| 2011-12-31 | CN¥421.45 Million | -10.59% |
| 2010-12-31 | CN¥471.37 Million | -39.94% |
| 2009-12-31 | CN¥784.81 Million | -20.67% |
| 2008-12-31 | CN¥989.24 Million | +21.47% |
| 2007-12-31 | CN¥814.38 Million | -0.98% |
| 2006-12-31 | CN¥822.47 Million | -2.10% |
| 2005-12-31 | CN¥840.14 Million | -5.55% |
| 2004-12-31 | CN¥889.56 Million | -9.51% |
| 2003-12-31 | CN¥983.02 Million | +13.42% |
| 2002-12-31 | CN¥866.67 Million | +39.59% |
| 2001-12-31 | CN¥620.88 Million | -11.04% |
| 2000-12-31 | CN¥697.92 Million | +0.86% |
| 1999-12-31 | CN¥691.94 Million | +46.24% |
| 1998-12-31 | CN¥473.15 Million | +257.87% |
| 1997-12-31 | CN¥132.21 Million | +0.51% |
| 1996-12-31 | CN¥131.54 Million | +98.31% |
| 1995-12-31 | CN¥66.33 Million | -- |